• Mashup Score: 0

    NICE has recommended glofitamab as a new treatment option for adults with relapsed or refractory diffuse large B cell lymphoma after 2 or more systemic treatments in final guidance published today (17 October 2023). Today’s recommendation for its use in the NHS coincides with glofitamab receiving its licence from the Medicines and Healthcare Products Regulatory Agency (MHRA). Lymphoma is a form of blood cancer that affects the immune system. It develops from a type of white blood cell, called a lymphocyte

    Tweet Tweets with this article
    • 🚨 NEWS 🚨 @NICEComms recommends glofitamab for the treatment of adult patients with relapsed or refractory diffuse large B-cell #lymphoma who have received two or more previous systemic treatments. Read more here: https://t.co/U0mjp7YHgu #lymsm #MedNews https://t.co/6znRbjhpuA